Its roles Owner Operator
Merck & Co., Inc. is a prominent American pharmaceutical company that specializes in the development and production of medicines, vaccines, and biologic products. Headquartered in the United States, it conducts extensive research and manufacturing activities across multiple states.
The company operates key facilities such as the Wilmington Merck Biologics site, the Durham Merck Vaccines plant, the Elkton Merck Pharmaceuticals and Vaccines location, the West Point Merck Vaccines and Biologics center, and the Riverside Merck Cherokee API facility. These sites support its involvement in centers of excellence for pharmaceutical manufacturing and expansions in vaccine production.
As a major player in the industry, Merck focuses on therapeutic areas including oncology, infectious diseases, and cardiovascular health. It is a publicly traded entity listed on major stock exchanges and maintains an independent structure separate from other entities with similar names.
Merck's contributions to the pharmaceutical sector include the production of innovative therapies that address global health needs, with operations primarily based in the US but extending internationally through its network.
Also known as MSD, Merck Sharp & Dohme, Merck Animal Health, MSD Animal Health, Merck Research Laboratories and 1 more.
chemXplore tracks 5 projects involving Merck, of which 2 are active.
Besides these 2, the record holds 3 completed projects.
Closest to start-up first.
The 3 that are completed, on hold or cancelled are in the record. See all 5 in chemXplore →
Phase 3 TroFuse‑005 showed a 32% lower risk of death and 41% lower risk of progression or death, with a PDUFA target date of June 15, 2027.
Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.
Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.
Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
A $550 million R&D expansion adds automated robotics and AI to streamline clinical-sample analysis and support a broad clinical development pipeline.
Early, multi-faceted plan includes seven royalty‑free licenses covering 129 LMICs, regional manufacturing support in Africa and Latin America, and early manufacturing investment to speed availability.
Merck invests $70B in U.S. manufacturing and R&D, creating 500+ full-time and 8,000 construction jobs in Virginia, enhancing biopharmaceutical innovation and domestic production.
active all projects
